The race to conquer multiple sclerosis (MS) is on, and Australian scientists are leading the charge. A recent breakthrough in understanding MS development could pave the way for more effective treatments and improved quality of life for those affected. Dr. Hamish King and his team at the Walter and Eliza Hall Institute of Medical Research (WEHI) have developed a groundbreaking method to study over 100 genetic risk factors for MS simultaneously. This is a significant advancement, as it allows researchers to explore the complex interplay between these factors and their impact on the immune system.
For years, scientists have known that numerous small genetic variations are associated with an increased risk of MS. However, the challenge has been deciphering how these variations contribute to the disease. Many of these genetic differences don't directly alter genes but instead influence how genes are regulated within immune cells, making it difficult to pinpoint their exact impact on the body.
Dr. King's innovative approach involves testing these genetic risk factors in human immune cells, examining their effects on gene activity and immune behavior both individually and collectively. This comprehensive study will provide valuable insights into how multiple genetic factors interact to initiate and progress MS.
Dr. King emphasizes the significance of this research, stating that understanding the complex interplay of genetic markers is crucial for unraveling the mysteries of MS. He highlights that MS can result from the cumulative effect of numerous small genetic variations, and this platform will enable scientists to study these changes collectively and identify the specific genes and pathways they influence.
The implications of this research are far-reaching. MS, an autoimmune condition where the body attacks the brain and spinal cord, causing damage to the protective myelin coating around nerve fibers, can significantly impact mobility, vision, cognitive abilities, and energy levels. The number of Australians living with MS has been steadily rising, reaching over 37,700 in 2025, with a 77.4% increase since 2010. The economic burden of MS is substantial, with a total cost of $3 billion in 2024.
Dr. Tennille Luker, MS Australia's Head of Research, underscores the importance of understanding genetic risk factors in driving the disease. She believes that identifying risks is just the beginning; it's the comprehension of how these genetic changes contribute to the disease that enables researchers to alter its course. MS Australia's commitment to research funding, exceeding $60 million over the past two decades, has been instrumental in advancing treatments and outcomes for MS patients.
The funding round also supports various research projects exploring different facets of MS. Associate Professor Anna Hatton at the University of Queensland is developing sensory shoe insoles to enhance balance for MS patients, aiming to improve signals sent from the feet to the brain. Professor Kaylene Young from the University of Tasmania's Menzies Institute is investigating the role of brain blood vessel changes in MS progression, exploring whether improving blood flow could protect nerve cells. Additionally, Alex Eisner at the Florey Institute and Dr. Brittney Lins at Curtin University are exploring the links between common viruses, copper levels, and MS risk factors.
The future of MS research looks promising, with sustained investment in research being vital for progress. MS Australia's CEO, Rohan Greenland, emphasizes the importance of continued research, stating that it offers hope and reminds MS patients that better treatments and prevention are within reach. This collective effort is bringing us closer to a world without MS, where the burden of this debilitating disease is significantly reduced.
